A Dose-Ranging Study With Vupanorsen (TRANSLATE-TIMI 70)
Status:
Active, not recruiting
Trial end date:
2021-12-14
Target enrollment:
Participant gender:
Summary
This is a multicenter, Phase 2b, double-blind, placebo-controlled, parallel group study to
provide data on efficacy, safety, tolerability, and pharmacokinetics (PK) of PF-07285557
(hereafter, vupanorsen) administered subcutaneously (SC) at various doses and regimens in
participants with dyslipidemia, defined in this study as participants with elevated non-HDL-C
and TG who are receiving a stable dose of a statin.
This study is also known as TaRgeting ANGPTL3 with an aNtiSense oLigonucleotide in AdulTs
with dyslipidEmia (TRANSLATE-TIMI 70).